Infinitopes Secures $15.4 Million for Innovative Cancer Vaccine Development and Trials
- Infinitopes secures $35.1 million to advance its innovative cancer vaccine development, targeting oesophageal cancer recurrence.
- The company collaborates with NHS cancer centers, aiming for the first clinical trial in early 2026, pending approvals.
- Partnerships with academia and funding support enhance Infinitopes’ focus on precision medicine and AI in cancer treatment.
Innovative Cancer Vaccine Development Receives Significant Funding Boost
Infinitopes, a clinical-stage cancer vaccine biotechnology company based in Oxford, recently announces the successful completion of its second close in a seed financing round, raising an additional $15.4 million. This brings the total funds secured to $35.1 million, a vital milestone for the company as it prepares for the upcoming first-in-human clinical trial of its precision cancer vaccine, ITOP1. Co-led by Octopus Ventures and new investor Amplify Bio, the financing round also sees participation from Macmillan Cancer Support, alongside notable existing investors such as Cancer Research Horizons and Manta Ray Ventures. The funding allows Infinitopes to advance its mission of developing innovative cancer therapies aimed at preventing recurrence in oesophageal cancer, an area with significant unmet clinical needs.
The Phase I/IIa VISTA trial is set to be conducted across multiple National Health Service (NHS) university cancer centers in the UK, with a targeted start date anticipated in the first quarter of 2026, pending regulatory approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Jonathan Kwok, CEO of Infinitopes, emphasizes the critical role of this funding in enabling the proof-of-concept evaluation of their AI/ML-precision targeted vaccine platform. He expresses gratitude for the support from Amplify Bio and Macmillan Cancer Support, which signifies a growing interest in innovative cancer treatments that leverage advanced technologies.
Amplify Bio’s Elliot Hershberg highlights the timely relevance of cancer vaccines and commends Infinitopes for its rigorous AI-powered immunomics profiling and scalable vaccine delivery vector. This strategic approach positions Infinitopes as a frontrunner in the fields of immunotherapy and precision oncology, aiming to deliver durable vaccines against various solid tumor types. The collaboration with Cancer Research UK and the University of Oxford further strengthens Infinitopes' capabilities in precision target discovery and efficient vector delivery, crucial for developing effective cancer vaccines.
In related developments, Infinitopes' commitment to advancing cancer treatment aligns with the broader industry trend toward integrating artificial intelligence in drug development. The increasing utilization of AI technologies in biopharmaceutical applications highlights the potential for more personalized and effective therapeutic options, particularly in oncology. As the company prepares for its clinical trials, the innovative strategies employed by Infinitopes signal a promising future for cancer patients seeking new hope in vaccine-based therapies.
The ongoing collaboration between academia and biotechnology firms, as evidenced by Infinitopes’ partnerships, plays a critical role in the advancement of cancer research. By securing substantial funding and focusing on precision medicine, Infinitopes is well-positioned to make significant contributions to the fight against cancer, ultimately improving patient outcomes and addressing unmet medical needs.